# Correction to “Efficacy and Safety of Bimekizumab in Patients With Psoriatic Arthritis With or Without Methotrexate: 52‐Week Results From Two Phase 3 Studies”

PMC · DOI: 10.1002/acr2.70086 · ACR Open Rheumatology · 2025-07-09

## Full-text entities

- **Diseases:** Psoriatic Arthritis (MESH:D015535)
- **Chemicals:** Methotrexate (MESH:D008727), Bimekizumab (MESH:C000625981)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12239507/full.md

---
Source: https://tomesphere.com/paper/PMC12239507